The patent, issued under the number US10166261, is for a method of managing dementia and dementia-related sleep disorders presented as symptoms of major depressive disorder (MDD) in humans associated with Irritable Bowel Syndrome (IBS) by administering Bacillus coagulans MTCC 5856 (LactoSpore) at a dose of 2 billion colony forming units per day.
The patent also mentions the ingredient’s ability to reduce serum myeloperoxidase, which is a biomarker of MDD.
The patent application was supported by a 2018 clinical study, published in the peer-reviewed journal Food & Nutrition Research titled “Bacillus coagulans MTCC 5856 for the management of major depression with irritable bowel syndrome: a randomised, doubleblind, placebo controlled, multi-centre, pilot clinical study.” The study showed LactoSpore was reported to reduce depression symptoms in adults with IBS.
“It is gratifying that the US patent office recognized the strain specific action of Sabinsa’s MTCC 5856 in allowing the claims,” said Shaheen Majeed, President Worldwide, Sabinsa. “We anticipate being granted patents on the discovery in additional countries in the near future.”
